Technical Analysis for PXMD - PaxMedica, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.07 | -50.11% | -0.07 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -50.11% | |
| Gilligan's Island Buy Setup | Bullish Swing Setup | -50.11% | |
| Narrow Range Bar | Range Contraction | -50.11% | |
| New 52 Week Low | Weakness | -50.11% | |
| Wide Bands | Range Expansion | -50.11% | |
| Below Lower BB | Weakness | -50.11% | |
| Gapped Down | Weakness | -50.11% | |
| Oversold Stochastic | Weakness | -50.11% | |
| 20 DMA Resistance | Bearish | -66.67% | |
| 50 DMA Resistance | Bearish | -66.67% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Gapped Down (Full) | about 3 hours ago |
| 2x Volume Pace | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
PaxMedica, Inc. Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Disorders Chronic Condition Drug Therapies Autism Spectrum Disorder Chronic Fatigue Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.659 |
| 52 Week Low | 0.13 |
| Average Volume | 11,088 |
| 200-Day Moving Average | 0.63 |
| 50-Day Moving Average | 0.23 |
| 20-Day Moving Average | 0.22 |
| 10-Day Moving Average | 0.21 |
| Average True Range | 0.04 |
| RSI (14) | 33.33 |
| ADX | 25.58 |
| +DI | 27.59 |
| -DI | 27.57 |
| Chandelier Exit (Long, 3 ATRs) | 0.20 |
| Chandelier Exit (Short, 3 ATRs) | 0.24 |
| Upper Bollinger Bands | 0.28 |
| Lower Bollinger Band | 0.17 |
| Percent B (%b) | -0.29 |
| BandWidth | 47.69 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.16 | ||||
| Resistance 3 (R3) | 0.16 | 0.15 | 0.16 | ||
| Resistance 2 (R2) | 0.15 | 0.15 | 0.15 | 0.16 | |
| Resistance 1 (R1) | 0.15 | 0.14 | 0.15 | 0.15 | 0.16 |
| Pivot Point | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 |
| Support 1 (S1) | 0.13 | 0.13 | 0.14 | 0.13 | 0.12 |
| Support 2 (S2) | 0.12 | 0.13 | 0.12 | 0.12 | |
| Support 3 (S3) | 0.12 | 0.12 | 0.12 | ||
| Support 4 (S4) | 0.12 |
